Portal de investigação
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Dados básicos
Objectivos do projeto
Ensaio Clínico - Iniciativa do Investigador; Fase: II – Aleatorizado e Controlado; Subtipo: Tratamento – Medicamento; Natureza do Promotor: Academia – Tipo não comercial; Tipo de Centro: Multicêntrico – 2 Centros de Cuidados Secundários – Centros de Ensaio: CHUSJ/CHVNGE; Doença investigada: Insuficiência cardíaca – Participantes recrutados: 86
Documentos
- Não há documentos
Participantes
-
Francisco Aguiar Vasques Novoa Faria
Investigador Colaborador
-
Joaquim Adelino Correia Ferreira Leite Moreira
Sub-Investigador
-
Ricardo Manuel Alves Monteiro Fontes De Carvalho
Sub-Investigador
-
Francisca Almeida Saraiva
Investigador Colaborador
-
João Pedro Melo Marques Pinho Ferreira
Investigador Principal
Unidades de investigação
-
RISE-Health
Investigador
Fernando Carlos De Landér Schmitt
Stakeholders - Promotores
Outputs do ensaio clínico
Automatic Contrast Generation from Contrastless Computed Tomography
Domingues, Ruben; (...); Renna, Francesco
Proceedings Paper. 10.1109/EMBC40787.2023.10340695. 2023
Glucose utilization by the trained heart: the molecular mechanisms behind fuel choice
Nogueira-Ferreira R.; (...); Ferreira R.
Book Chapter. 10.1016/B978-0-323-91704-9.00015-X. 2023
Glycolysis in pulmonary arterial hypertension and metabolic reprogramming
Vasconcelos I.; (...); Adão R.
Book Chapter. 10.1016/B978-0-323-91704-9.00008-2. 2023
Heart failure: pathophysiology and the emergence of novel therapies
Silva-Cardoso J.; (...); Leite-Moreira A.
Book Chapter. 10.1016/B978-0-323-99991-5.00016-4. 2023
LoRaWAN Based Street Lighting for Remote Areas with Shadow Zones
Ferreira, Joao; (...); Agreira, C. I. Faustino
Proceedings Paper. 10.1109/MELECON56669.2024.10608473. 2024
Pancreatic ß cells: the metabolic network underlying body’s glucostat
Ferreira R.; (...); Neves J.S.
Book Chapter. 10.1016/B978-0-323-91704-9.00005-7. 2023
Useful bioinformatics approaches for studying pathological conditions characterized by the dysregulation of glucose metabolism
Reumiller C.M.; (...); Trindade F.
Book Chapter. 10.1016/B978-0-323-91704-9.00003-3. 2023
?UFO: Unidentified Flying Object in the Heart?: An Unusual Sighting of a Cardiac Calcified Amorphous Tumour
Ribeiro Silva, M; (...); Fontes Carvalho, R.
Article. 10.4250/jcvi.2022.0139. 2023
2022 Year in Review
Sorgente, A; (...); Enriquez-Sarano, ML
Article. 10.1016/j.jaccas.2022.101727. 2023
A 4-variable model to predict cardio-kidney events and mortality in chronic kidney disease: The Chronic Renal Insufficiency Cohort (CRIC) Study
Mendon?a, L.; (...); Ferreira, J.
Article. 10.1159/000533223. 2023
A 4-variable model to predict cardio-kidney events and mortality in chronic kidney disease: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Mendonça, LCF; (...); Ferreira, JP
Article. 10.1159/000533223. 2023
A challenging case of prosthetic mitral valve dysfunction: the value of multimodality imaging
Duarte, F; (...); Fontes-Carvalho, R
Editorial Material. 10.1007/s10554-023-03028-0. 2023
A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial
Kobayashi, M; (...); Girerd, N
Article. 10.1002/ejhf.2859. 2023
A meta-analysis of randomized controlled studies comparing off-pump vs on-pump CABG in the elderly
Machado, RJ; (...); Leite-Moreira, AF
Meeting Abstract. 2021
A prospective study on varicose veins surgery impact on systemic endothelial function evaluated by arterial brachial flow mediated dilation
Nóbrega, L; (...); Castro-Ferreira, R
Article. 10.1177/17085381231175707. 2023
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19
Sharma, A; (...); Ferreira, JP
Article. 10.1016/j.ahj.2022.01.015. 2022
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19.
Sharma, A; (...); Ferreira, JP
Article. 10.1016/j.ahj.2022.01.015. 2022
A Starr-Edwards Prosthesis Can Last Forever (But Its Sutures May Not)
Nunes, Fabio Sousa; (...); Neves, Fatima Sousa
Editorial Material. 10.1016/j.hjc.2024.03.011. 2024
A systematic review and meta-analysis of randomized controlled studies comparing off-pump versus on-pump coronary artery bypass grafting in the elderly
Machado, RJ; (...); Leite Moreira, AF
Review. 10.23736/S0021-9509.21.12012. 2022
Actual adherence to dimethyl fumarate in patients with relapsing-remitting multiple sclerosis
de Sá, J, Ferreira, J, Macedo, AM
Article. 10.33588/rn.76S01.2022296. 2023
Acute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction
Moreira-Costa L.; (...); Lourenço A.P.
Article. 10.1016/j.ejphar.2024.176336. 2024
Acute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction.
Moreira-Costa, L; (...); Lourenço, AP
Article. 10.1016/j.ejphar.2024.176336. 2024
Adverse events associated with early initiation of Eplerenone in patients hospitalized for acute heart failure
Kobayashi M.; (...); Ferreira J.P.
Article. 10.1016/j.ijcard.2024.132477. 2024
Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes
Ferreira, J.; (...); Neves, J.
Article. 10.1002/ejhf.2660. 2022
Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes.
Ferreira, JP; (...); Neves, JS
Article. 10.1002/ejhf.2660. 2022
An Analysis From a Tertiary Pediatric Hospital: Does Physical Activity Play a Role in the Management of Children and Young Adults With Osteogenesis Imperfecta?
Saraiva, Francisca Galhardo; (...); Campagnolo, Joao Lameiras
Article. 10.7759/cureus.53646. 2024
Aortic stenosis progression among patients with bicuspid aortic valve
Teixeira, R.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Aortic stenosis rapid progression is associated with premature cardiac damage independently of baseline severity
Teixeira, R; (...); Fontes-Carvalho, R
Meeting Abstract. 2023
Aortic Valve Surgery in Patients with Infective Endocarditis: Mid-Term Follow-up of Patients Treated With the ST. Jude Medical Trifecta Valve.
Silva B; (...); Leite-Moreira A
Article. 10.48729/pjctvs.283. 2022
Artificial intelligence and colon capsule endoscopy: Automatic detection of ulcers and erosions using a convolutional neural network
Ribeiro, T; (...); Macedo, G.
Article. 10.1111/jgh.16011. 2022
Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments: an analysis from the Swedish Heart Failure Registry
Schrage, B; (...); Savarese, G
Article. 10.1002/ejhf.2928. 2023
Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments: An analysis from the Swedish Heart Failure Registry.
Schrage, B; (...); Savarese, G
Article. 10.1002/ejhf.2928. 2023
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure A Secondary Analysis of EMPEROR-Pooled
Ferreira, JP; (...); Packer, M
Article. 10.1001/jamacardio.2022.2924. 2022
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure A Secondary Analysis of EMPEROR-Pooled. - A Secondary Analysis of EMPEROR-Pooled.
Ferreira, JP; (...); Packer, M
Article. 2022
Association of metabolic syndrome components and NAFLD with quality of life: Insights from a cross-sectional study
Borges-Canha M.; (...); Neves J.S.
Article. 10.1016/j.pcd.2024.01.004. 2024
Association of thyroid function, within the euthyroid range, with cardiovascular risk: The EPIPorto study
Neves, J.; (...); Azevedo, A.
Article. 10.3389/fendo.2022.1067801. 2022
Authors reply in response to a letter on "Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study"
Roncon Albuquerque, R.; (...); Paiva, JA
Letter. 10.1186/s13613-023-01215-9. 2023
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial
Ravassa, S; (...); González, A
Article. 10.1002/ejhf.2394. 2022
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Pocock, SJ; (...); Anker, SD
Article. 10.1002/ejhf.2607. 2022
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Pocock, SJ; (...); Anker, SD
Article. 10.1002/ejhf.2607. 2022
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
Packer, M; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.123.065748. 2023
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
Packer, M; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.123.065748. 2023
Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial
Ferreira, J.; (...); Zannad, F
Article. 10.1159/000519436. 2022
Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial.
Ferreira, JP; (...); Zannad, F
Article. 10.1159/000519436. 2022
Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial
Sattar N.; (...); Anker S.D.
Article. 10.1002/ejhf.3221. 2024
Body mass index effect on long-term survival after coronary artery bypass surgery: a competing risk analysis
Abreu, A; (...); Leite-Moreira, A
Article. 10.1093/icvts/ivad161. 2023
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial
Ferreira, J.; (...); Zannad, F
Article. 10.1186/s12933-021-01382-8. 2021
Candidate microRNAs as prognostic biomarkers in heart failure: A systematic review
Figueiredo, R; (...); Brás-Silva, C
Review. 10.1016/j.repc.2021.03.020. 2022
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme
Ferreira, JP; (...); Januzzi, JL
Article. 10.1002/ejhf.3166. 2024
Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial
Sharma, A; (...); Anker, SD
Article. 10.1002/ejhf.2857. 2023
Cardiac Remodeling and Diastolic Dysfunction in Paroxysmal Atrial Fibrillation
Noirclerc, N; (...); Girerd, N
Article. 10.3390/jcm10173894. 2021
Cardiac remodelling and reverse remodelling in pregnant women: what can be expected?
Ferreira, AF; (...); Fa, I
Meeting Abstract. 2021
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
Colombo G.; (...); Inciardi R.M.
Review. 10.1002/ehf2.15095. 2024
Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas
Ferreira, JP; (...); Zannad, F
Article. 10.1016/j.ijcard.2022.01.053. 2022
Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas.
Ferreira, JP; (...); Zannad, F
Article. 10.1016/j.ijcard.2022.01.053. 2022
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
Ferreira, J.; (...); Zannad, F
Article. 10.1161/JAHA.120.020053. 2021
Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF
Sharma, A; (...); Zannad, F
Article. 10.1136/bmjopen-2022-068865. 2023
Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF.
Sharma, A; (...); Zannad, F
Article. 10.1136/bmjopen-2022-068865. 2023
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial
Neves J.S.; (...); Ferreira J.P.
Article. 10.1002/ejhf.3478. 2024
Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial
Razaghizad, A; (...); Sharma, A
Article. 10.1111/dom.15768. 2024
Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed
Ferreir, Joao Pedro, Neves, Joao Sergio, Saraiva, Francisca
Editorial Material. 10.1016/j.cardfail.2023.12.002. 2024
Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed.
Ferreira, JP, Neves, JS, Saraiva, F
Article. 10.1016/j.cardfail.2023.12.002. 2024
Cardiovascular remodelling and reverse remodelling during pregnancy and postpartum: Looking at the right side
Ferreira A.F.; (...); Falcão-Pires I.
Article. 10.1016/j.preghy.2024.101171. 2024
Cardiovascular risk factors during pregnancy impact the postpartum cardiac and vascular reverse remodeling
Ferreira, AF; (...); Falcao-Marques, I
Article. 10.1152/ajpheart.00200.2023. 2023
Cardiovascular risk factors during pregnancy impact the postpartum cardiac and vascular reverse remodeling (vol 325, pg H774, 2023)
Ferreira, Ana Filipa; (...); Falcao-Pires, Ines
Correction. 10.1152/ajpheart.00200.2023_COR. 2024
Catastrophic presentation of peripartum cardiomyopathy: a case report of a challenging diagnosis
Silva, MR; (...); Fontes Carvalho, R.
Article. 10.1093/ehjcr/ytac395. 2022
Catheter ablation for atypical atrial flutter: characterization and recurrence predictors
Barradas, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Circulating Biomarkers and Cardiac Structure and Function in Rheumatoid Arthritis
Kobayashi, M; (...); Ferreira, J.
Article. 10.3389/fcvm.2021.754784. 2021
Circulating levels of procollagen type I carboxy-terminal propeptide reflect myocardial fibrosis
Ferreira, J.
Editorial Material. 10.1002/ejhf.2216. 2021
Clinical and Pathophysiologic Insights of Free triiodothyronine/Free thyroxine Ratio in Patients with Heart Failure with Preserved Ejection Fraction: Data from the NETDiamond Cohort
Leite, AR; (...); Leite-Moreira, A
Article. 10.1159/000530136. 2023
Clinical and Pathophysiologic Insights of Free triiodothyronine/Free thyroxine Ratio in Patients with Heart Failure with Preserved Ejection Fraction: Data from the NETDiamond Cohort.
Leite, AR; (...); Leite Moreira, A
Article. 10.1159/000530136. 2023
Clinical associations and prognostic implications of 6-minute walk test in rheumatoid arthritis
Ferreira, MB; (...); Ferreira, JP
Article. 10.1038/s41598-022-21547-z. 2022
Clinical associations and prognostic implications of 6-minute walk test in rheumatoid arthritis.
Ferreira, MB; (...); Ferreira, JP
Article. 10.1038/s41598-022-21547-z. 2022
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF
Shen L.; (...); McMurray J.J.V.
Article. 10.1161/CIRCULATIONAHA.124.070553. 2024
Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis
Razaghizad, A; (...); Sharma, A
Review. 10.1161/JAHA.121.024833. 2022
Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Razaghizad, A; (...); Sharma, A
Review. 10.1161/JAHA.121.024833. 2022
Clinical relevance of the blanking period on late recurrence after catheter ablation of atrial fibrillation
Silva, MR; (...); Fontes Carvalho, R.
Article. 10.1111/jce.15729. 2023
Clinical relevance of the blanking period on late recurrence after catheter ablation of atrial fibrillation.
Silva, MR; (...); Fontes Carvalho, R
Article. 10.1111/jce.15729. 2023
Combined central and peripheral demyelination after COVID-19 vaccination
Coelho, P; (...); Albuquerque, L
Letter. 10.1007/s00415-022-11188-7. 2022
Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study
Ferreira J.P.; (...); Leite-Moreira A.
Article. 10.1016/j.atherosclerosis.2024.117461. 2024
Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study.
Ferreira, JP; (...); Leite-Moreira, A
Article. 10.1016/j.atherosclerosis.2024.117461. 2024
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial
Carson, P; (...); Packer, M
Article. 10.1016/j.jchf.2022.11.017. 2023
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial.
Carson, P; (...); Packer, M
Article. 2023
Comprehensive characterization of protein modifications using mass spectrometry and dry blood spots
Guedes, S; (...); Vitorino, R.
Article. 10.1002/prca.202300102. 2024
Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial
Packer, M; (...); Zannad, F
Article. 10.1002/ejhf.2256. 2021
Concomitant left atrial and left ventricular masses: lessons to clinical practice
Brandao, M; (...); Fontes-Carvalho, R
Article. 10.1093/ehjci/jeac236. 2022
Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement: Feasibility in clinical practice
Silva, G; (...); Fontes-Carvalho, R
Article. 10.1016/j.repc.2022.10.012. 2023
Coronary Artery Disease and Aortic Valve Stenosis: A Urine Proteomics Study
Perpetuo, L; (...); Vitorino, R.
Article. 10.3390/ijms232113579. 2022
Corrigendum: Reverse left ventricular remodeling after aortic valve replacement for aortic stenosis: a systematic review and meta-analysis(Front. Cardiovasc. Med., (2024), 11, (1407566), 10.3389/fcvm.2024.1407566)
Sousa Nunes F.; (...); Sousa C.
Correction. 10.3389/fcvm.2024.1471225. 2024
Corticotropin-releasing hormone and obesity: From fetal life to adulthood
Vasconcelos I.; (...); Brás-Silva C.
Review. 10.1111/obr.13763. 2024
Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design
Pellicori, P; (...); Sanyal, AJ
Review. 10.1016/j.diabet.2021.101281. 2022
Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design.
Pellicori, P; (...); Sanyal, AJ
Review. 10.1016/j.diabet.2021.101281. 2022
Current clinical use of speckle-tracking strain imaging: insights from a worldwide survey from the European Association of Cardiovascular Imaging (EACVI)
Sade, LE; (...); Dweck, MR
Article. 10.1093/ehjci/jead170. 2023
Current role and future perspectives of artificial intelligence in echocardiography
Vidal-Perez, R; (...); Vazquez-Rodriguez, JM
Review. 10.4330/wjc.v15.i6.284. 2023
Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis
Angelico Goncalves, A; (...); Ferreira, J.
Article. 10.1016/j.ijcard.2023.05.032. 2023
Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis.
Angelico Goncalves, A; (...); Ferreira, JP
Article. 10.1016/j.ijcard.2023.05.032. 2023
DEEP LEARNING AND DIGITAL SINGLE-OPERATOR CHOLANGIOSCOPY (DSOC): AUTOMATIC DIAGNOSIS OF MALIGNANCY STATUS AND MORPHOLOGICAL CHARACTERIZATION OF BILIARY STRICTURES.
Saraiva, MM; (...); Macedo, G
Meeting Abstract. 2022
Dependability evaluation and sensitivity analysis of data center cooling systems
Souza, Lubnnia; (...); Ferreira, Joao
Article. 10.1007/s11227-023-05419-5. 2023
Detailed safety analysis of DIAMOND trial: 'primum non nocere'?
Baptista, R, Gonçalves, S, Fontes-Carvalho, R
Editorial Material. 10.1093/eurheartj/ehad473. 2023
DEVELOPMENT OF A CONVOLUTIONAL NEURAL NETWORK FOR AUTOMATIC DETECTION AND PHENOTYPIC DIFFERENTIATION OF PANCREATIC CYSTIC LESIONS
Ribeiro, TF; (...); Macedo, G
Meeting Abstract. 2022
Differences in biomarkers and molecular pathways according to age for patients with HFrEF
Ferreira, J.; (...); Zannad, F
Article. 10.1093/cvr/cvaa279. 2021
Digital flashcards and medical physiology performance: a dose-dependent effect
Santos-Ferreira D.; (...); Leite-Moreira A.
Article. 10.1152/advan.00138.2023. 2024
Digital flashcards and medical physiology performance: a dose-dependent effect.
Santos Ferreira, D; (...); Leite Moreira, A
Article. 10.1152/advan.00138.2023. 2024
Digital follow-up program for patients undergoing atrial fibrillation ablation: a pilot single-center study
Brandao, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Digital health and cardiovascular healthcare professionals in Portugal: Current status, expectations and barriers to implementation
Queiroz, Carlota; (...); Ladeiras-Lopes, Ricardo
Article. 10.1016/j.repc.2023.10.014. 2024
Digitisation of patient preferences in palliative care: mobile app prototype
Ferreira, J; (...); Campos, MJ
Article. 10.1136/spcare-2023-004516. 2023
DISSECTING SEXUAL DIMORPHISM IN AORTIC VALVE STENOSIS BY PROTEOMICS
Grego, Ana; (...); Trindade, Fabio
Meeting Abstract. 2024
Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?
Ferreira J.P., MENDONÇA L.U.Í.S., NEVES J.S.
Article. 10.1016/j.cardfail.2024.05.006. 2024
Door-to-furosemide time and clinical outcomes in acute heart failure
Marques, P; (...); Frioes, F
Article. 10.1097/MEJ.0000000000001006. 2023
Door-to-furosemide time and clinical outcomes in acute heart failure
Brito, MT; (...); Marques, P
Meeting Abstract. 2022
Door-to-furosemide time and clinical outcomes in acute heart failure.
Marques, P; (...); Frioes, F
Article. 10.1097/MEJ.0000000000001006. 2023
Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial
Ferreira, J.; (...); Zannad, FAB -
Article. 10.1002/ejhf.2255. 2021
Doxorubicin-induced cardiotoxicity - Are plants the answer?
Mendes-Ferreira P, Leite-Moreira AF
Article. 10.1016/j.repc.2024.10.003. 2024
Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial.
Monzo, L; (...); Zannad, F
Article. 10.1002/ehf2.14086. 2022
Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial
Monzo, L; (...); Zannad, F
Article. 10.1002/ehf2.14086. 2022
Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial
Ferreira, JP; (...); Rossignol, P
Letter. 10.1007/s00392-022-02116-w. 2023
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial
Butler, J; (...); Anker, SD
Editorial Material. 10.1002/ejhf.2420. 2022
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved
Rastogi, T; (...); Zannad, F
Article. 10.1002/ejhf.3136. 2024
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced
Zannad, F; (...); Packer, M
Article. 10.1002/ejhf.2578. 2022
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.
Zannad, F; (...); Packer, M
Article. 10.1002/ejhf.2578. 2022
Early-onset atherosclerosis in a patient with Tangier disease: Not all that is gold glitters
Silva, G; (...); Fontes-Carvalho, R
Editorial Material. 10.33963/KP.a2023.0061. 2023
Echocardiographic assessment of the right heart in patients with aortic stenosis undergoing transcatheter aortic valve implantation: analysis from a large single-center cohort
Brandao, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
Butler, J; (...); Anker, SD
Article. 10.1093/eurheartj/ehab798. 2022
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
Zannad, F; (...); Packer, M
Article. 10.1093/eurheartj/ehac495. 2022
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme.
Zannad, F; (...); Packer, M
Article. 10.1093/eurheartj/ehac495. 2022
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial
Packer, M; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.121.056824. 2021
Effect of eplerenone on clinical stability of Japanese patients with acute heart failure
Kobayashi, M; (...); Kitakaze, M
Article. 10.1016/j.ijcard.2022.12.045. 2023
Effect of eplerenone on clinical stability of Japanese patients with acute heart failure.
Kobayashi, M; (...); Kitakaze, M
Article. 10.1016/j.ijcard.2022.12.045. 2023
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials
Leite, AR; (...); Ferreira, J.
Article. 10.1111/dom.14707. 2022
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.
Leite, AR; (...); Ferreira, JP
Article. 10.1111/dom.14707. 2022
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
Dewan P.; (...); McMurray J.J.V.
Article. 10.1161/CIRCULATIONAHA.124.068774. 2024
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)
Ferreira, JP; (...); Zannad, F
Article. 10.1016/j.amjcard.2022.12.016. 2023
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial).
Ferreira, JP; (...); Zannad, F
Article. 10.1016/j.amjcard.2022.12.016. 2023
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
Butler, J; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.122.059755. 2022
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
Butler, J; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.122.059755. 2022
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced
Filippatos, G; (...); Packer, M
Article. 10.1002/ejhf.2707. 2022
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced.
Filippatos, G; (...); Packer, M
Article. 10.1002/ejhf.2707. 2022
Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.3101. 2023
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
Kosiborod, MN; (...); Voors, AA
Article. 10.1161/CIRCULATIONAHA.122.059725. 2022
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
Kosiborod, MN; (...); Voors, AA
Article. 10.1161/CIRCULATIONAHA.122.059725. 2022
Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial
Ferreira, JP; (...); Wanner, C
Meeting Abstract. 2022
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES
Yeoh, SE; (...); McMurray, JJAB -
Article. 10.1002/ejhf.2350. 2022
Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial
Wei, FF; (...); Staessen, JA
Article. 10.1038/s41440-024-01843-z. 2024
Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure
Vaduganathan, MM; (...); Solomon, SD
Article. 10.1002/ejhf.2635. 2022
Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure.
Vaduganathan, M; (...); Solomon, SD
Article. 10.1002/ejhf.2635. 2022
Effects of Triiodothyronine Treatment in an Animal Model of Heart Failure with Preserved Ejection Fraction
Neves, J.; (...); Leite Moreira, A.
Article. 10.1089/thy.2022.0717. 2023
Effects of Triiodothyronine Treatment in an Animal Model of Heart Failure with Preserved Ejection Fraction.
Neves, JS; (...); Leite Moreira, A
Article. 10.1089/thy.2022.0717. 2023
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF
Dhingra, NK; (...); Packer, M
Article. 10.1016/j.jchf.2023.06.036. 2024
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF.
Dhingra, NK; (...); Packer, M
Article. 2024
Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results From the EMPULSE Trial
Voors, AA; (...); Ponikowski, P
Meeting Abstract. 2021
Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved
Coats, AJS; (...); Anker, SD
Article. 10.1002/jcsm.13393. 2024
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Anker, SD; (...); Zannad, F
Article. 10.1038/s41591-022-02041-5. 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
Anker, SD; (...); Zannad, F
Article. 10.1038/s41591-022-02041-5. 2022
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories
Butler, J; (...); Zannad, F
Article. 10.1016/j.jacc.2023.03.390. 2023
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.
Butler, J; (...); Zannad, F
Article. 10.1016/j.jacc.2023.03.390. 2023
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Balasubramanian, P; (...); Inzucchi, SE
Article. 10.1210/clinem/dgac154. 2022
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?.
Balasubramanian, P; (...); Inzucchi, SE
Article. 2022
Empagliflozin and Major Renal Outcomes in Heart Failure
Packer, M; (...); Anker, SD
Letter. 10.1056/NEJMc2112411. 2021
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis
Ferreira, JP; (...); Anker, S
Article. 10.1002/ejhf.3180. 2024
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled
Ferreira, JP; (...); Packer, M
Article. 10.1093/eurheartj/ehac306. 2022
EMPAGLIFLOZIN AND SERUM POTASSIUM IN HEART FAILURE: AN ANALYSIS FROM EMPEROR-POOLED
Ferreira, JP
Meeting Abstract. 2022
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled ( ehac306, 2022)
Ferreira, JP; (...); Packer, M
Correction. 10.1093/eurheartj/ehac428. 2022
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
Ferreira, JP; (...); Packer, M
Article. 2022
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial
Ferreira, J.; (...); Zinman, B
Article. 10.1111/dom.14559. 2022
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.
Ferreira, JP; (...); Zinman, B
Article. 10.1111/dom.14559. 2022
Empagliflozin benefits in patients with heart failure and preserved ejection fraction
Anker, SD; (...); Zannad, F
Editorial Material. 10.1038/s41591-022-02050-4. 2022
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
Filippatos, G; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.122.059785. 2022
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
Filippatos, G; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.122.059785. 2022
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
Böhm, M; (...); Packer, M
Article. 10.1016/j.jacc.2021.07.049. 2021
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
Böhm, M; (...); Anker, SD
Article. 10.1016/j.jacc.2022.04.040. 2022
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
Böhm, M; (...); Anker, SD
Article. 10.1016/j.jacc.2022.04.040. 2022
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled
Verma, S; (...); Packer, M
Letter. 10.1161/CIRCULATIONAHA.122.062644. 2023
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Anker, SD; (...); Packer, M
Article. 10.1056/NEJMoa2107038. 2021
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation
Filippatos, G; (...); Anker, SD
Article. 10.1002/ejhf.2861. 2023
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.
Filippatos, G; (...); Anker, SD
Article. 10.1002/ejhf.2861. 2023
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
Verma, S; (...); Packer, M
Article. 10.1016/S2213-8587(21)00292-8. 2022
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Dhingra N.K.; (...); Lobo Márquez L.
Article. 10.1016/S2213-8587(21)00292-8. 2022
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Butler, J; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.121.057812. 2022
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Butler, J; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.121.057812. 2022
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Böhm, M; (...); Butler, J
Article. 2022
Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes
Ribeiro, Eduarda; (...); Vale, Nuno
Article. 10.3390/jcm13144113. 2024
Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes.
Ribeiro, E; (...); Vale, N
Article. 10.3390/jcm13144113. 2024
Epicardial adipose tissue volume is not an independent predictor of atrial fibrillation recurrence after catheter ablation
Cruz, I; (...); Fontes Carvalho, R.
Article. 10.1016/j.rec.2022.11.006. 2023
Epicardial adipose tissue volume is not an independent predictor of atrial fibrillation recurrence after catheter ablation.
Cruz, I; (...); Fontes-Carvalho, R
Article. 2023
Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors
Marques, P; (...); Ferreira, JP
Article. 10.1002/ejhf.2992. 2023
Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors.
Marques, P; (...); Ferreira, JP
Article. 10.1002/ejhf.2992. 2023
Exercise training counteracts the cardiac metabolic remodelling induced by experimental pulmonary arterial hypertension
Morais, F; (...); Moreira-Gonçalves, D
Article. 10.1016/j.abb.2022.109419. 2022
External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial
Razaghizad, A; (...); Zannad, F
Article. 10.1111/dom.14867. 2023
External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial.
Razaghizad, A; (...); Zannad, F
Article. 10.1111/dom.14867. 2023
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction An Exploratory Analysis of a Phase 3 Randomized Clinical Trial
Docherty, KF; (...); McMurray, JJV
Article. 10.1001/jamacardio.2021.2632. 2021
Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffness
Bäck M.; (...); Rossignol P.
Article. 10.1093/ehjopen/oeac016. 2022
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD
Ferreira, J.; (...); Leite Moreira, A.
Article. 10.2337/dc21-1977. 2022
Ferritin, inflammation, and iron deficiency in acute heart failure: evidence from the EDIFICA cohort
Vasques-Nóvoa F.; (...); Friões F.
Article. 10.1007/s00392-024-02535-x. 2024
FIB-4 Index should Guide the Referral of Patients with Metabolic Syndrome to Gastroenterology: The Perspective of a Portuguese Cohort
Borges-Canha, M; (...); Freitas, P
Article. 10.26497/ao230023. 2023
FIB-4 Index should Guide the Referral of Patients with Metabolic Syndrome to Gastroenterology: The Perspective of a Portuguese Cohort.
Borges Canha, M; (...); Freitas, P
Article. 2023
Flow-status and survival in severe aortic stenosis treated with TAVI - is flow rate superior to stroke volume index?
Santos Ferreira, D. A.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2022
Galectin-3 in prostate cancer and heart diseases: a biomarker for these two frightening pathologies?
Lima T.; (...); Vitorino R.
Review. 10.1007/s11033-022-08207-1. 2023
Global longitudinal strain: Ready for prime time' in heart failure characterization
Donal, E, Neveu, A, Fontes-Carvalho, R
Editorial Material. 10.1002/ejhf.3012. 2023
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
Neves, J.; (...); Md, JPF
Article. 10.1016/j.jacc.2023.05.048. 2023
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.
Neves, JS; (...); Md, JPF
Article. 10.1016/j.jacc.2023.05.048. 2023
Glucagon-like peptide 1 receptor agonists in heart failure: the need for a rewind
Ferreira, J., Neves, J.
Editorial Material. 10.1002/ejhf.2693. 2022
Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials
Ferreira, J.; (...); Neves, J.
Article. 10.1111/dom.14997. 2023
Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
Ferreira, JP; (...); Neves, JS
Article. 10.1111/dom.14997. 2023
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
Ferreira, J.; (...); Neves, J.
Review. 10.1210/clinem/dgad398. 2023
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure.
Ferreira, JP; (...); Neves, JS
Review. 2023
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.3078. 2024
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program.
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.3078. 2024
Health status across major subgroups of patients with heart failure and preserved ejection fraction
Siddiqi, TJ; (...); Butler, J
Article. 10.1002/ejhf.2831. 2023
Health status across major subgroups of patients with heart failure and preserved ejection fraction.
Siddiqi, TJ; (...); Butler, J
Article. 10.1002/ejhf.2831. 2023
Heart failure care: The time has come to tackle the cardiovascular "epidemic" of the XXI century
Santos-Ferreira, D, Fontes-Carvalho, R
Editorial Material. 10.1016/j.repc.2023.09.002. 2023
Heart Failure in Brazil and the Need to Measure and Take Action
Rivas-Lasarte, M, Ferreira, JP
Editorial Material. 10.1016/j.cardfail.2023.10.485. 2024
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial
Böhm, M; (...); Anker, SD
Article. 10.1002/ejhf.2677. 2022
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial.
Böhm, M; (...); Anker, SD
Article. 10.1002/ejhf.2677. 2022
Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure
Wei F.-F.; (...); Staessen J.A.
Article. 10.1002/ehf2.15000. 2024
Heterotopic Tricuspid Valve Implantation
Russo, G, Fontes Carvalho, R., Taramasso, M
Article. 10.1016/j.jaccas.2022.09.030. 2023
High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial
Monzo, L; (...); Zannad, F
Article. 10.1016/j.cardfail.2023.11.020. 2024
High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.
Monzo, L; (...); Zannad, F
Article. 10.1016/j.cardfail.2023.11.020. 2024
High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL
Ferreira, JP; (...); Zannad, F
Article. 10.1016/j.cardfail.2022.09.008. 2023
High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL.
Ferreira, JP; (...); Zannad, F
Article. 10.1016/j.cardfail.2022.09.008. 2023
High- versus low-dose losartan and uric acid: An analysis from HEAAL
Ferreira, JP; (...); Konstam, MA
Article. 10.1016/jucc.2023.04.005. 2023
High- versus low-dose losartan and uric acid: An analysis from HEAAL.
Ferreira, JP; (...); Konstam, MA
Article. 10.1016/j.jjcc.2023.04.005. 2023
Higher coronary artery calcium score is associated with increased risk of atrial fibrillation recurrence after catheter ablation
Fernandes, SL; (...); Fontes Carvalho, R.
Article. 10.1016/j.jcct.2022.10.002. 2023
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT
Ferreira, JP; (...); Solomon, SD
Article. 10.1016/j.ijcard.2024.131818. 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT.
Ferreira, JP; (...); Solomon, SD
Article. 10.1016/j.ijcard.2024.131818. 2024
Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity
Ferreira, JP, Pitt, B, Zannad, F
Review. 10.1016/S2666-7568(21)00061-1. 2021
Home- versus centre-based EXercise InTervention in patients with Heart Failure (EXIT-HF trial): A pragmatic randomized controlled trial
Schmidt, C; (...); Santos, M
Article. 10.1016/j.repc.2023.05.013. 2024
Home- versus clinic-based exercise intervention in patients with heart failure (EXIT-HF trial): a pragmatic randomized controlled trial
Santos, M; (...); Ribeiro, F
Meeting Abstract. 2023
HUMAN IPSC ORGANOID PRODUCTION FOR PATIENT-SPECIFIC LIVER BIOFABRICATION
Martins-Santos, R; (...); Goldenberg, R
Meeting Abstract. 2023
Human-umbilical cord matrix mesenchymal cells improved left ventricular contractility independently of infarct size in swine myocardial infarction with reperfusion
Raposo, L; (...); Leite-Moreira, A
Article. 10.3389/fcvm.2023.1186574. 2023
Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension
Kasiakogias, A; (...); Kreutz, RAB -
Article. 10.1097/HJH.0000000000002910. 2021
Identification of sex-specific biomarkers predicting new-onset heart failure
Raafs, A; (...); Heymans, SAB -
Article. 10.1002/ehf2.13476. 2021
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced
Ferreira, JP; (...); Packer, M
Article. 10.1002/ejhf.2409. 2022
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.
Ferreira, JP; (...); Packer, M
Article. 10.1002/ejhf.2409. 2022
Impact of cardiovascular risk factors in vascular remodelling of pregnant women
Ferreira, AF; (...); Falcao-Pires, I
Meeting Abstract. 2021
Impact of coronary artery calcium score screening on cardiovascular risk stratification of patients with atrial fibrillation undergoing ablation
Fernandes, S; (...); Ladeiras-Lopes, R
Article. 10.1159/000532018. 2023
Impact of disease duration on proteomic bioprofile and prognosis in rheumatoid arthritis patients
Brandao, M; (...); Ferreira, JP
Article. 10.55563/clinexprheumatol/ua087b. 2023
Impact of disease duration on proteomic bioprofile and prognosis in rheumatoid arthritis patients.
Brandão, M; (...); Ferreira, JP
Article. 10.55563/clinexprheumatol/ua087b. 2023
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
Khan, MS; (...); Packer, M
Article. 10.1161/JAHA.122.027652. 2023
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.
Khan, MS; (...); Packer, M
Article. 10.1161/JAHA.122.027652. 2023
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
Biegus, J; (...); Ponikowski, P
Article. 10.1093/eurheartj/ehac530. 2023
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.
Biegus, J; (...); Ponikowski, P
Article. 10.1093/eurheartj/ehac530. 2023
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis
Talha, KM; (...); Packer, M
Article. 10.1111/dom.15572. 2024
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial
Ferreira, J.; (...); Zannad, F
Article. 10.1161/CIRCHEARTFAILURE.120.008075. 2021
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE
Dewan, P; (...); McMurray, JJV
Article. 10.1002/ejhf.2856. 2023
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE.
Dewan, P; (...); McMurray, JJV
Article. 2023
Impact of prediabetes in heart failure with preserved ejection fraction: the NetDiamond cohort
Borges-Canha, M; (...); Leite-Moreira, A
Meeting Abstract. 2021
Impact of smoking on cardiovascular risk and premature ageing: Findings from the STANISLAS cohort
Rastogi, T; (...); Ferreira, JP
Article. 10.1016/j.atherosclerosis.2022.02.017. 2022
Impact of smoking on cardiovascular risk and premature ageing: Findings from the STANISLAS cohort.
Rastogi, T; (...); Ferreira, JP
Article. 10.1016/j.atherosclerosis.2022.02.017. 2022
Improved SWMM Modeling for Rapid Pipe Filling Incorporating Air Behavior in Intermittent Water Supply Systems
Ferreira, JP; (...); Kapelan, Z
Article. 10.1061/JHEND8.HYENG-13137. 2023
Improving risk stratification of moderate aortic stenosis
Teixeira, R.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
In Vitro Drug Repurposing: Focus on Vasodilators
Ribeiro, Eduarda; (...); Vale, Nuno
Review. 10.3390/cells12040671. 2023
In Vitro Drug Repurposing: Focus on Vasodilators.
Ribeiro, E; (...); Vale, N
Review. 10.3390/cells12040671. 2023
Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials
Neves, J., Packer, M, Ferreira, J.
Article. 10.1016/j.cardfail.2023.03.017. 2023
Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials.
Neves, JS, Packer, M, Ferreira, JP
Article. 10.1016/j.cardfail.2023.03.017. 2023
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.2455. 2022
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.2455. 2022
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial
Packer, M; (...); Anker, SD
Letter. 10.1002/ejhf.2334. 2021
Influence of iron deficiency definition on the efficacy of intravenous iron in heart failure: a meta-analysis of randomized trials
Marques P.; (...); Ferreira J.P.
Article. 10.1007/s00392-024-02557-5. 2024
Influence of race in the estimation of glomerular filtration rate in patients with a high cardiovascular and renal risk
Ferreira, JP; (...); Rossignol, P
Letter. 10.1093/ckj/sfab246. 2022
Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury
Garcia, Bruno; (...); Herpain, Antoine
Article. 10.1186/s40635-024-00638-3. 2024
Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme
Ferreira J.P.; (...); Januzzi J.L.
Article. 10.1002/ejhf.3227. 2024
Interaction of natriuretic peptide levels and ejection fraction on outcomes with dapagliflozin and empagliflozin in heart failure
Butler, J; (...); Packer, M
Letter. 10.1002/ejhf.2854. 2023
Interleukin-6, infection and cardiovascular outcomes in acute heart failure: Findings from the EDIFICA registry
Vasques-Nóvoa, F; (...); Frioes, F
Article. 10.1016/j.cyto.2022.156053. 2022
Intracoronary imaging guided percutaneous coronary intervention of stent restenosis: does it make a difference?
Barradas, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Investigação Clínica da Iniciativa do Investigador em Portugal: Identificação de Problemas e Propostas para Melhoria. - Investigator-Led Clinical Research in PortugalProblem Identification and Proposals for Improvement.
Ferreira, JP; (...); Resende Oliveira, C
Article. 2023
Investigator-Led Clinical Research in Portugal: Problem Identification and Proposals for Improvement
Ferreira, JP; (...); Oliveira, CR
Article. 10.20344/amp.19333. 2023
Is Reducing Heart Failure Hospitalization Associated With Reducing Mortality in Heart Failure Trials?
Marques P., Sharma A., Ferreira J.P.
Editorial Material. 10.1016/j.jchf.2024.01.011. 2024
Isolated diastolic hypertension and target organ damage: Findings from the STANISLAS cohort
Monzo, L; (...); Rossignol, PAB -
Article. 10.1002/clc.23713. 2021
Ketones' impact on a dysmetabolic rat model of HFpEF
Goncalves, A; (...); Falcao-Pires, I
Meeting Abstract. 2023
Large animal models of pressure overload-induced cardiac left ventricular hypertrophy to study remodelling of the human heart with aortic stenosis
Beslika E.; (...); da Costa Martins P.A.
Article. 10.1093/cvr/cvae045. 2024
Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: Anti-AQP4 positive, anti-MOG positive and seronegative subgroups
Santos, E; (...); Sá, MJ
Article. 10.1016/j.msard.2022.103845. 2022
Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction
Büttner P.; (...); Adams V.
Article. 10.1002/ehf2.15111. 2024
Left atrial strain evaluation to assess left ventricle diastolic dysfunction and heart failure with preserved ejection fraction: a guide to clinical practice Left atrial strain and diastolic function
Silva, MR; (...); Fontes Carvalho, R.
Article. 10.1007/s10554-023-02816-y. 2023
Letter of reply to the letter by Ryan
Ferreira, J.; (...); Neves, J.
Letter. 10.1111/dom.14743. 2022
Letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial
Ferreira, J., Neves, J.
Letter. 10.1002/ejhf.2694. 2022
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial
Böhm, M; (...); Anker, SD
Article. 10.1002/ejhf.2922. 2023
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial.
Böhm, M; (...); Anker, D
Article. 10.1002/ejhf.2922. 2023
Long-Term Exposure to Supraphysiological Levels of Testosterone Impacts Rat Submandibular Gland Proteome
Valente-Santos, J; (...); Amado, F
Article. 10.3390/ijms25010550. 2024
Long-term survival of female versus male patients after coronary artery bypass grafting
Abreu, A, Máximo, J, Leite-Moreira, A
Article. 10.1371/journal.pone.0275035. 2022
Lung ultrasound and diuretic therapy in chronic heart failure: a randomised trial
Cruz, M; (...); Pimenta, J
Article. 10.1007/s00392-023-02238-9. 2023
Lung ultrasound and diuretic therapy in chronic heart failure: a randomised trial.
Cruz, M; (...); Pimenta, J
Article. 10.1007/s00392-023-02238-9. 2024
Machine Learning-Derived Echocardiographic Phenotypes Predict Heart Failure Incidence in Asymptomatic Individuals
Kobayashi, M; (...); Girerd, N
Article. 10.1016/j.jcmg.2021.07.004. 2022
Machine Learning-Derived Echocardiographic Phenotypes Predict Heart Failure Incidence in Asymptomatic Individuals.
Kobayashi, M; (...); Girerd, N
Article. 10.1016/j.jcmg.2021.07.004. 2022
Management of Heart Failure With Reduced Ejection Fraction in Patients With Diabetes Mellitus and Chronic Kidney Disease
Khan M.S.; (...); Butler J.
Review. 10.1016/j.semnephrol.2023.151429. 2023
Management of Renin-Angiotensin-Aldosterone System Blockade in Patients Admitted in Hospital With Confirmed Coronavirus Disease (COVID-19) Infection: The McGill RAAS-COVID-19 Randomized Controlled Trial
Sharma, A; (...); Ferreira, JP
Meeting Abstract. 2021
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
Zannad F.; (...); Harrison S.A.
Review. 10.1111/joim.13793. 2024
Mec?nica Ventricular Esquerda: Desvendando as Vias da Resposta Cardiovascular ao Exerc?cio
Vilela, EM, Fontes Carvalho, R.
Article. 10.36660/abc.20230181. 2023
Metabolic Syndrome and the Risk of Preclinical Heart Failure: Insights after 17 Years of Follow-Up from the STANISLAS Cohort
Sharma, A; (...); Zannad, F
Article. 10.1159/000523717. 2022
Metabolic Syndrome and the Risk of Preclinical Heart Failure: Insights after 17 Years of Follow-Up from the STANISLAS Cohort.
Sharma, A; (...); Zannad, F
Article. 2022
Metabolomics and Cardiovascular Risk in Patients with Heart Failure: A Systematic Review and Meta-Analysis
Neves, LS; (...); Diaz, SO
Review. 10.3390/ijms25115693. 2024
Metformin Prevents Endothelial Dysfunction in Endometriosis through Downregulation of ET-1 and Upregulation of eNOS
Martins, AF; (...); Neves, D
Article. 10.3390/biomedicines10112782. 2022
Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials
Ferreira J.P.; (...); Neves J.S.
Article. 10.1159/000541686. 2024
Mineralocorticoid receptor antagonist indication and underuse in high-risk post-myocardial infarction patients
Ferreira, JP, Rossello, X, Zannad, F
Editorial Material. 10.1002/ejhf.3098. 2023
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE
Ferreira, JP; (...); Voors, AA
Article. 10.1002/ejhf.2982. 2023
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.
Ferreira, JP; (...); Voors, AA
Article. 10.1002/ejhf.2982. 2023
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction
Ferreira, J.; (...); Anker, SD
Article. 10.1016/j.jacc.2022.01.029. 2022
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
Ferreira, JP; (...); Anker, SD
Article. 10.1016/j.jacc.2022.01.029. 2022
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update
Ferreira, JP, Pitt, B, Zannad, F
Review. 10.1161/CIRCHEARTFAILURE.124.011629. 2024
Missed opportunities in the diagnosis of heart failure: a real-world assessment
Ferreira, JP; (...); Gavina, C
Article. 10.1002/ehf2.14531. 2023
Missed opportunities in the diagnosis of heart failure: a real-world assessment.
Ferreira, JP; (...); Gavina, C
Article. 10.1002/ehf2.14531. 2023
Mitochondrial remodeling underlying age-induced skeletal muscle wasting: let's talk about sex
Moreira-Pais A.; (...); Duarte J.A.
Article. 10.1016/j.freeradbiomed.2024.04.005. 2024
Modeling aortic stenosis progression: impact on follow-up, treatment and survival
Teixeira, R; (...); Fontes-Carvalho, R
Meeting Abstract. 2022
Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF
Markousis-Mavrogenis, G; (...); van der Meer, P
Article. 10.1093/cvr/cvab235. 2022
Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF.
Markousis-Mavrogenis, G; (...); van der Meer, P
Article. 2022
Multiple versus single arterial grafting in the elderly: a meta-analysis of randomized controlled trials and propensity score studies
Saraiva, FA; (...); Leite Moreira, A.
Review. 10.23736/S0021-9509.21.11826-9. 2022
Myocardial deformation analysis using cardiac magnetic resonance in apical hypertrophic cardiomyopathy: is it an useful tool to predict adverse outcomes?
Fernandes, RM; (...); Fontes-Carvalho, R
Article. 10.1007/s10554-023-02902-1. 2023
Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock
Garcia, B; (...); Herpain, A
Article. 10.1186/s13054-022-04161-3. 2022
Myocardial phosphoproteomics and single cardiomyocyte force measurements endorse DYRK1A as a candidate therapeutic target for incomplete reverse remodelling after aortic valve replacement
Trindade, FF; (...); Falcao-Pires, I
Meeting Abstract. 2023
Myocardial RNA Sequencing Reveals New Potential Therapeutic Targets in Heart Failure with Preserved Ejection Fraction
Inacio, JM; (...); Belo, JA
Article. 10.3390/biomedicines11082131. 2023
Myocardial stretch-induced compliance is abrogated under ischemic conditions and restored by cGMP/PKG-related pathways
Leite Moreira, AM; (...); Louren?o, A.
Article. 10.3389/fphys.2023.1271698. 2023
Myocardial stretch-induced compliance is abrogated under ischemic conditions and restored by cGMP/PKG-related pathways.
Leite Moreira, AM; (...); Lourenço, AP
Article. 10.3389/fphys.2023.1271698. 2023
Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction
Almeida-Coelho, J; (...); leite-moreira, af
Letter. 10.1161/CIRCHEARTFAILURE.124.011833. 2024
National registries for rare clinical conditions: Networking to promote evidence-based healthcare
Leite-Moreira, AF, Saraiva, F
Editorial Material. 10.1016/j.repc.2023.03.007. 2023
Neuromyelitis optica spectrum disorders: A nationwide Portuguese clinical epidemiological study
Santos, E; (...); Sá, MJ
Article. 10.1016/j.msard.2021.103258. 2021
New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial
Ferreira, J.; (...); Zannad, FAB -
Article. 10.1007/s00392-021-01891-2. 2022
No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial
Ferreira, JP; (...); Zannad, F
Letter. 10.1016/j.acvd.2021.10.003. 2021
Noblestitch Failure After Percutaneous Patent Foramen Ovale Closure in a Case Of Platypnea-Orthodeoxia Syndrome: Is this Device Suitable for All Patients?
Moura, AR; (...); Fontes Carvalho, R.
Article. 10.36660/abcimg.2022309i. 2023
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial
Pocock, SJ; (...); Packer, M
Article. 10.1093/eurheartj/ehab579. 2021
Nuclear tension controls mitotic entry by regulating cyclin B1 nuclear translocation
Dantas, M; (...); Ferreira, J.
Article. 10.1083/jcb.202205051. 2022
Obituary: Paulo Bettencourt 1965-2021
Lourenço, P; (...); Ferreira, AL
Biographical-Item. 10.1002/ejhf.2359. 2021
Office- versus home-based evaluation of quality of life in heart failure with reduced ejection fraction: A randomized study
de Almeida Pinho I.; (...); Ferreira J.P.
Article. 10.1016/j.ijcard.2024.132341. 2024
Off-pump versus on-pump coronary artery bypass grafting: a propensity score-matching analysis of safety and long-term results
Saraiva, FA; (...); Leite-Moreira, AF
Meeting Abstract. 2021
Omecamtiv Mecarbil A Personalized Treatment for Patients With Severely Impaired Ejection Fraction
Ferreira, J.AB -
Editorial Material. 10.1016/j.jacc.2021.04.077. 2021
On the Impact of Synchronous Electrocardiogram Signals for Heart Sounds Segmentation
Silva, A; (...); Renna, F
Proceedings Paper. 10.1109/EMBC40787.2023.10341149. 2023
One more piece in the puzzle of stem cell therapy in cardiovascular diseases;
Nogueira-Ferreira R., Leite-Moreira A.F.
Note. 10.1016/j.repc.2024.08.007. 2024
Optimization of a Protocol for Protein Extraction from Calcified Aortic Valves for Proteomics Applications: Development of a Standard Operating Procedure
Trindade, F; (...); Vitorino, R
Article. 10.3390/proteomes10030030. 2022
Optimization of a Protocol for Protein Extraction from Calcified Aortic Valves for Proteomics Applications: Development of a Standard Operating Procedure.
Trindade, F; (...); Vitorino, R
Article. 10.3390/proteomes10030030. 2022
Optimizing heart failure pathways to enhance patient care: the Program to Optimize Heart Failure Patient Pathways (PRO-HF)
Patwala, Ashish; (...); Mebazaa, Alexandre
Article. 10.1002/ehf2.14911. 2024
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions
Anker, SD; (...); Butler, J
Article. 10.1002/ejhf.2558. 2022
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions.
Anker, SD; (...); Butler, J
Article. 10.1002/ejhf.2558. 2022
Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT
Ferreira, J.; (...); Zannad, FAB -
Article. 10.1002/ejhf.2376. 2022
Pathophysiological and therapeutic implications of urocortin-2 in heart failure with preserved ejection fraction
Adao, R; (...); Bras-Silva, C
Meeting Abstract. 2022
Pathophysiological Sex Differences in Heart Failure Progression AfterAcute Coronary Syndrome: Insights From the EXAMINE Trial
Razaghizad, A; (...); Sharma, A
Article. 10.1016/j.cardfail.2023.10.474. 2024
Pathophysiological Sex Differences in Heart Failure Progression AfterAcute Coronary Syndrome: Insights From the EXAMINE Trial.
Razaghizad, A; (...); Sharma, A
Article. 2024
Patiromer and MRA Doses in Patients With Current or Past Hyperkalemia
Ferreira J.P.
Editorial Material. 10.1016/j.jchf.2024.07.020. 2024
Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure
Kobayashi, M; (...); Ferreira, J.AB -
Article. 10.1002/clc.23576. 2021
Pericardial Fluid Accumulates microRNAs That Regulate Heart Fibrosis after Myocardial Infarction
Silva, ED; (...); Nascimento, DS
Article. 10.3390/ijms25158329. 2024
Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial.
Santos Ferreira, D; (...); Zannad, F
Article. 10.1002/ehf2.14465. 2024
Portuguese Heart Failure Prevalence Observational Study (PORTHOS) rationale and design - A population-based study
Baptista, R; (...); Gavina, C.
Article. 10.1016/j.repc.2023.10.004. 2023
Predictive Risk Score for Acute Kidney Injury in Hematopoietic Stem Cell Transplant
Rodrigues, N; (...); Lopes, JA
Article. 10.3390/cancers15143720. 2023
Predictors for NYHA recovery and 1-year mortality after mitral TEER
Santos Ferreira, D. A.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2022
Predictors of AF recurrence in patients with paroxysmal AF undergoing catheter ablation: new predictors coming?
Ribeiro Silva, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2022
Predictors of left ventricular dysfunction in hypertrophic cardiomyopathy: results from a nationwide registry
Brandao, M.; (...); Portuguese Registry Hypertrophic
Meeting Abstract. 2022
Predictors of mortality in patients with advanced heart failure and cardiac resynchronization therapy
Brochado, L.; (...); Leite-Moreira, A.
Meeting Abstract. 2023
Preoperative smoking status and long-term survival after coronary artery bypass grafting: a competing risk analysis
Abreu A., Máximo J.D., Leite-Moreira A.
Article. 10.1093/ejcts/ezae183. 2024
Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled
Verma, S; (...); Packer, M
Letter. 10.1161/ATVBAHA.123.319156. 2023
Prognostic association of circulating relaxin-2 in acute heart failure
Pintalhao M.; (...); Castro-Chaves P.
Article. 10.1016/j.ijcard.2024.132358. 2024
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved
Januzzi, JL; (...); Anker, SD
Article. 10.1016/j.jchf.2022.05.004. 2022
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.
Januzzi, JL; (...); Anker, SD
Article. 2022
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
Januzzi, JL; (...); Packer, M
Article. 10.1016/j.jacc.2021.07.046. 2021
Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial
Martens, P; (...); Rossignol, P
Article. 10.1093/ehjacc/zuab111. 2022
Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial.
Martens, P; (...); Rossignol, P
Article. 10.1093/ehjacc/zuab111. 2022
Prognostic value of flow-status in severe aortic stenosis patients undergoing percutaneous intervention
Santos-Ferreira, D; (...); Fontes-Carvalho, R
Article. 10.1007/s10554-023-02992-x. 2023
Prognostic value of flow-status in severe aortic stenosis patients undergoing percutaneous intervention.
Santos Ferreira, D; (...); Fontes Carvalho, R
Article. 10.1007/s10554-023-02992-x. 2024
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study
Girerd, N; (...); Zannad, F
Article. 10.1161/CIRCHEARTFAILURE.122.009694. 2023
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study.
Girerd, N; (...); Zannad, F
Article. 10.1161/CIRCHEARTFAILURE.122.009694. 2023
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial
Verdonschot, JAJ; (...); Heymans, SRB
Article. 10.1186/s12933-021-01357-9. 2021
Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort
Kobayashi M.; (...); Girerd N.
Article. 10.1002/ejhf.3202. 2024
Proteomics for understanding progression to heart failure in chronic kidney disease: promising but still not there
Zannad F., Ferreira J.P.
Editorial Material. 10.1093/eurheartj/ehae399. 2024
Quality of life after pulmonary veins isolation: outcomes from a digital follow-up program
Teixeira, R.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire
Ravera, A; (...); Voors, AAAB -
Article. 10.1002/ejhf.2154. 2021
Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program
Packer M.; (...); Zannad F.
Article. 10.1016/j.jacc.2024.07.013. 2024
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin An EMPEROR-Pooled Analysis
Ferreira, JP; (...); Packer, M
Article. 10.1016/j.jchf.2023.01.018. 2023
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin An EMPEROR-Pooled Analysis.
Ferreira, JP; (...); Packer, M
Article. 2023
Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure
Ferreira, J.; (...); Zannad, F
Editorial Material. 10.1002/ejhf.2457. 2022
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Lam, CSP; (...); Packer, M
Article. 10.1093/eurheartj/ehab360. 2021
Relaxin-2, pathophysiological insights and outcomes in heart failure with preserved ejection fraction: Findings from the NETDiamond cohort
Pintalhao, M; (...); Leite Moreira, A.
Article. 10.1016/j.ijcard.2022.07.037. 2022
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
Voors, AA; (...); Ponikowski, P
Article. 10.1002/ejhf.2681. 2022
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
Voors, AA; (...); Ponikowski, P
Article. 10.1002/ejhf.2681. 2022
Reply to 'Empagliflozin and glucagon-like peptide-1 receptor agonists: The brothers for heart failure?'
Ferreira, JP, Voors, AA
Editorial Material. 10.1002/ejhf.3415. 2024
Reply to Letter to the Editor regarding the article ?Suboptimal control of cardiovascular risk factors in myocardial infarction survivors in a cardiac rehabilitation program?
Silva, V; (...); Fontes-Carvalho, R
Article. 10.1016/j.repc.2022.10.006. 2022
Reply to the letter entitled “Inflammation in Heart Failure with Preserved Ejection Fraction: A Bystander or A Participant?” by Zhong M and Yan X
Ferreira J.P., Zannad F., Solomon S.D.
Letter. 10.1016/j.ijcard.2024.132278. 2024
Representativeness of EXPLORER-HCM trial and prevalence of eligibility criteria for Mavacamten in a nationwide cohort
Brandao, M.; (...); Portuguese Registry Hypertrophic
Meeting Abstract. 2022
Response and long-term outcomes with resynchronization therapy: the role of heart failure etiology
Brandao, M.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2022
Response to Letter to Editor From Banerjee et al: "Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure"
Ferreira, JP, Neves, JS
Letter. 10.1210/clinem/dgad507. 2023
Resposta da Press?o Arterial e Ecocardiografia sob Estresse F?sico: Novas Perspectivas sobre um Desafio Contempor?neo
Vilela, EM, Fontes Carvalho, R.
Article. 10.36660/abc.20230737. 2023
RETRACTED: Valve-in-valve TAVI for treatment of degenerated surgical aortic bioprosthesis (Retracted article. See vol. 119, 2023)
Silva, Mariana Ribeiro; (...); Fontes-Carvalho, Ricardo
Meeting Abstract. 10.1093/cvr/cvac157.020. 2022
RETRACTED: Vascular access computed tomography angiography-derived iliofemoral calcium volume in the evaluation of vascular and bleeding complications after transfemoral TAVI (Retracted article. See vol. 119, 2023)
Silva, Mariana Ribeiro; (...); Fontes-Carvalho, Ricardo
Meeting Abstract. 10.1093/cvr/cvac157.075. 2022
Retrieval of a dislodged stent during transcatheter aortic valve replacement
Silva, MR; (...); Fontes Carvalho, R.
Article. 10.1007/s12928-023-00913-2. 2023
Reverse left ventricular remodeling after aortic valve replacement for aortic stenosis: a systematic review and meta-analysis
Sousa Nunes F.; (...); Sousa C.
Review. 10.3389/fcvm.2024.1407566. 2024
Reverse Translation of Pericardial Access: Pericardial Catheter Implantation in Mice
Mendes-Ferreira P., Leite-Moreira A.M., Leite-Moreira A.F.
Editorial Material. 10.1016/j.jacbts.2024.08.007. 2024
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
Neves, J.; (...); Ferreira, J.
Article. 10.1111/dom.14862. 2023
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial.
Neves, JS; (...); Ferreira, JP
Article. 10.1111/dom.14862. 2023
Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France
Baudry, G; (...); Girerd, N
Article. 10.1002/ejhf.3103. 2023
Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France.
Baudry, G; (...); Girerd, N
Article. 2023
Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: The REMI study
Monzo L.; (...); Girerd N.
Article. 10.1002/ejhf.2986. 2023
Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: The REMI study.
Monzo, L; (...); Girerd, N
Article. 10.1002/ejhf.2986. 2023
Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal
Santos, M; (...); de Sá, J
Review. 10.1097/WNF.0000000000000552. 2023
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction A Post Hoc Analysis of the EMPEROR-Preserved Trial
Butler, J; (...); Anker, S
Article. 10.1001/jamacardio.2023.1090. 2023
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction. - A Post Hoc Analysis of the EMPEROR-Preserved Trial.
Butler, J; (...); Anker, S
Article. 10.1001/jamacardio.2023.1090. 2023
Sarcopenia as a Prognostic Factor in Peripheral Arterial Disease: Descriptive Review
Ferreira, J.; (...); Correia Neves, M
Article. 10.1016/j.avsg.2021.01.076. 2021
Semaglutide and Cardiovascular Outcomes
Neves, JS, Leite, AR, Ferreira, JP
Letter. 10.1056/NEJMc2400414. 2024
Sex differences and survival after TAVI for severe aortic stenosis
Ferreira, D. A. Santos; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Sex differences in aortic stenosis progression and myocardial response
Teixeira, R.; (...); Fontes-Carvalho, R.
Meeting Abstract. 2023
Sex differences in circulating proteins of patients with rheumatoid arthritis: A cohort study
Ferreira, MB; (...); Ferreira, JP
Article. 10.1111/1756-185X.14323. 2022
Sex differences in circulating proteins of patients with rheumatoid arthritis: A cohort study.
Ferreira, MB; (...); Ferreira, JP
Article. 10.1111/1756-185X.14323. 2022
Sex-based differences and risk of recurrence in patients with atrial fibrillation undergoing pulmonary vein isolation
Aguiar-Neves, Ines; (...); Fontes-Carvalho, Ricardo
Article. 10.1016/j.ijcard.2024.132161. 2024
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction - The New Frontier
Aguiar-Neves, I, Santos-Ferreira, D, Fontes-Carvalho, R
Article. 10.31083/j.rcm2401001. 2023
Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?
Neves J.S.; (...); Ferreira J.P.
Article. 10.1016/j.jacc.2024.06.026. 2024
Sixty years of the Bruce protocol: reappraising the contemporary role of exercise stress testing with electrocardiographic monitoring
Vilela, EM; (...); Fontes Carvalho, R.
Article. 10.1097/j.pbj.0000000000000235. 2023
Size does matter: a simple swine model of chronic pulmonary hypertension
Moreira-Costa, L; (...); Mendes-Ferreira, P
Meeting Abstract. 10.1183/13993003.congress-2023.PA440. 2023
Social media use by cardiovascular healthcare professionals in Portugal
Esteves-Pereira, M; (...); Ladeiras-Lopes, R
Article. 10.1016/j.repc.2022.03.010. 2023
Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations
Butler, J; (...); Packer, MAB -
Editorial Material. 10.1093/eurheartj/ehab704. 2021
Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis
Ferreira, JP; (...); Leite-Moreira, A
Article. 10.1530/EJE-20-1484. 2021
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.2726. 2023
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.2726. 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials
Ferreirra, JP; (...); Zannad, F
Article. 10.1016/j.ijcard.2023.01.088. 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
Ferreira, JP; (...); Zannad, F
Article. 10.1016/j.ijcard.2023.01.088. 2023
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial
Ferreira, J.; (...); Zannad, F
Article. 10.1093/ehjcvp/pvab031. 2022
Staging cardiac damage in patients with aortic regurgitation
Silva, G; (...); Sampaio, F
Article. 10.1007/s10554-022-02673-1. 2022
Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study
Roncon Albuquerque, R.; (...); Paiva, J.
Article. 10.1186/s13613-023-01185-y. 2023
Steroidal MRA Across the Spectrum of Renal Function
Ferreira, JP; (...); Rossignol, P
Article. 10.1016/j.jchf.2022.06.010. 2022
Steroidal MRA Across the Spectrum of Renal Function.
Ferreira, JP; (...); Rossignol, P
Article. 2022
Stretch-induced compliance mechanism in pregnancy-induced cardiac hypertrophy and the impact of cardiovascular risk factors
Ferreira A.F.; (...); Falcão-Pires I.
Article. 10.1152/ajpheart.00701.2023. 2024
Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort
Alexandre A.; (...); Rodrigues P.
Article. 10.1007/s00392-024-02548-6. 2024
Subclinical Thyroid Dysfunction and Cardiovascular Disease
Lourenco, IM; (...); Neves, JS
Review. 10.26497/ar230029. 2023
Subclinical Thyroid Dysfunction and Cardiovascular Disease.
Lourenco, IM; (...); Neves, JS
Review. 2023
Synchronous spontaneous coronary artery dissection after pregnancy: when the two happen at once
Silva, G; (...); Fontes Carvalho, R.
Article. 10.1097/mca.0000000000001172. 2023
TARGETING PREMATURE AGING TO IMPROVE HFPEF
Silva, E. D.; (...); Nascimento, D. S.
Meeting Abstract. 2023
The additive effects of anaemia and transfusion on long-term survival after coronary artery bypass surgery
Abreu A.; (...); Leite-Moreira A.
Article. 10.1093/ejcts/ezad403. 2024
The additive role of cardiac CT in a patient with cardiogenic shock and suspected mechanical complication of myocardial infarction
Temtem, M; (...); Fontes-Carvalho, R
Editorial Material. 10.1093/ehjci/jead066. 2023
The Association between Gestational Diabetes and the Microbiome: A Systematic Review and Meta-Analysis
Teixeira, RA; (...); Barros, A.
Review. 10.3390/microorganisms11071749. 2023
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial
Kobayashi, M; (...); Zannad, F
Article. 10.1002/ejhf.2579. 2022
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Kobayashi, M; (...); Zannad, F
Article. 10.1002/ejhf.2579. 2022
The Best Articles of 2022 in the Arquivos Brasileiros de Cardiologia and Revista Portuguesa de Cardiologia
de Oliveira, GMM; (...); Rochitte, CE
Review. 10.36660/abc.20230342. 2023
The best articles of 2022 in the Arquivos Brasileiros de Cardiologia and Revista Portuguesa de Cardiologia
de Oliveira G.M.M.; (...); Rochitte C.E.
Article. 10.1016/j.repc.2023.10.001. 2023
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial
Verdonschot, JAJ; (...); Heymans, SRB
Article. 10.1016/j.cardfail.2021.12.005. 2022
The Effect of the Stress Induced by Hydrogen Peroxide and Corticosterone on Tryptophan Metabolism, Using Human Neuroblastoma Cell Line (SH-SY5Y).
Correia, AS; (...); Vale, N
Article. 10.3390/ijms24054389. 2023
The extent of postpartum cardiac reverse remodeling is reflected in urine proteome
Ferreira A.F.; (...); Barros A.S.
Article. 10.1038/s41598-024-65612-1. 2024
The Future of Meat. Health Impact Assessment with Randomized Evidence
Ferreira, J., Sharma, A, Zannad, FAB -
Review. 10.1016/j.amjmed.2020.11.007. 2021
The Heart as a ?Balance? in Everyday and After Life: Lessons From Ancient Egypt
Vilela, E, Fontes Carvalho, R.
Article. 10.1016/j.jaccas.2023.102010. 2023
The impact of echocardiographic indexation to evaluate cardiac reverse remodeling throughout pregnancy and postpartum
Ferreira, AF; (...); Falcao-Pires, I
Article. 10.1016/j.repc.2023.04.014. 2024
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes A Meta-Analysis of Randomized Placebo-Controlled Trials
Mendonça, L; (...); Ferreira, JP
Article. 10.2215/CJN.0000000584. 2024
The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
Leite, M; (...); Fontes Carvalho, R
Article. 10.1002/ehf2.14284. 2023
The impact of pre-existing right bundle brunch block on short and mid-term outcomes after transcatheter aortic valve implantation
Silva, Mariana Ribeiro; (...); Fontes-Carvalho, Ricardo
Meeting Abstract. 2022
The PERInatal MYocardial Remodeling (PERIMYR) cohort study protocol: A prospective study of cardiac remodeling and "recovery" in pregnancy as a model to understand the impact of comorbidities in cardiac remodeling and reverse remodeling
Ferreira, AF; (...); Falcao-Pires, I
Article. 10.1016/j.repc.2022.08.015. 2023
The SAFEST study: The crucial role of primary health care in the diagnosis and management of atrial fibrillation
Gon?alves-Teixeira, P; (...); Fontes Carvalho, R.
Article. 10.1016/j.repc.2023.04.015. 2024
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Voors, AA; (...); Ponikowski, P
Article. 10.1038/s41591-021-01659-1. 2022
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors, AA; (...); Ponikowski, P
Article. 10.1038/s41591-021-01659-1. 2022
The Use of Radiomic Analysis in Cardiovascular Diseases.
Vieira Santos-Silva M; (...); Dias-Neto M
Article. 10.48729/pjctvs.286. 2022
The win ratio in cardiology trials: lessons learnt, new developments, and wise future use
Pocock, SJ; (...); Stone, GW
Review. 10.1093/eurheartj/ehae647. 2024
The win ratio method in heart failure trials: lessons learnt from EMPULSE
Pocock, SJ; (...); Voors, AA
Article. 10.1002/ejhf.2853. 2023
The win ratio method in heart failure trials: lessons learnt from EMPULSE.
Pocock, SJ; (...); Voors, AA
Article. 10.1002/ejhf.2853. 2023
The year 2021 in the European Heart Journal-Cardiovascular Imaging: Part I
Edvardsen, T; (...); Cosyns, B
Article. 10.1093/ehjci/jeac210. 2022
Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization
Henry, A; (...); Lumbers, RT
Article. 10.1161/CIRCULATIONAHA.121.056663. 2022
Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization.
Henry, A; (...); Lumbers, RT
Article. 10.1161/CIRCULATIONAHA.121.056663. 2022
Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE
Ferreira, JP; (...); Voors, AA
Article. 10.1002/ejhf.3369. 2024
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from the EMPHASIS-HF trial
Monzo, L; (...); Zannad, F
Article. 10.1002/ejhf.2952. 2023
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from the EMPHASIS-HF trial.
Monzo, L; (...); Zannad, F
Article. 10.1002/ejhf.2952. 2023
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction
Bedrouni, W; (...); Zannad, F
Letter. 10.1161/CIRCHEARTFAILURE.121.009295. 2022
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial
Tromp J.; (...); Voors A.A.
Article. 10.1002/ejhf.3218. 2024
Ulcerated Gastric Lipoma Presenting with Gastrointestinal Bleeding and Hypovolemic Shock
Ferreira, J., Santos, A, Germano, A
Article. 10.5334/jbsr.2700. 2022
Unraveling the Impact of miR-146a in Pulmonary Arterial Hypertension Pathophysiology and Right Ventricular Function
Santos-Gomes, J; (...); Brás-Silva, C
Article. 10.3390/ijms25158054. 2024
Unravelling the Gut Microbiome Role in Cardiovascular Disease: A Systematic Review and a Meta-Analysis
Martins, D; (...); Miranda, IM
Review. 10.3390/biom14060731. 2024
Unsupervised clustering to differentiate rheumatoid arthritis patients based on proteomic signatures
Ferreira, MB; (...); Ferreira, JP
Article. 10.1080/03009742.2023.2196781. 2023
Unsupervised clustering to differentiate rheumatoid arthritis patients based on proteomic signatures.
Ferreira, MB; (...); Ferreira, JP
Article. 10.1080/03009742.2023.2196781. 2023
Unveiling Human Proteome Signatures of Heart Failure with Preserved Ejection Fraction
Sebastiao, MJ; (...); Gomes-Alves, P
Article. 10.3390/biomedicines10112943. 2022
Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Doehner W.; (...); Packer M.
Article. 10.1016/j.jchf.2024.08.020. 2024
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
Doehner, W; (...); Packer, M
Article. 10.1093/eurheartj/ehac320. 2022
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
Doehner, W; (...); Packer, M
Article. 10.1093/eurheartj/ehac320. 2022
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
Yu, YL; (...); Staessen, JA
Article. 10.1136/heartjnl-2023-323796. 2024
Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance
Ferreira, JP; (...); Franco, F
Article. 10.1002/ehf2.14090. 2022
Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance.
Ferreira, JP; (...); Franco, F
Article. 10.1002/ehf2.14090. 2022
Value of cardiac magnetic resonance on the risk stratification of cardiomyopathies
Vidal-Perez, R; (...); Vazquez-Rodriguez, JM
Review. 10.4330/wjc.v15.i10.487. 2023
Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial
Khan, MS; (...); Butler, J
Article. 10.1016/j.cardfail.2023.06.024. 2023
Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial.
KHAN, MS; (...); BUTLER, J
Article. 10.1016/j.cardfail.2023.06.024. 2023
Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20-Year Follow-Up
Kanbay, M; (...); Rossignol, P
Article. 10.1161/JAHA.121.023301. 2022
Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20-Year Follow-Up.
Kanbay, M; (...); Rossignol, P
Article. 10.1161/JAHA.121.023301. 2022
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced
Anker, SD; (...); Packer, M
Article. 10.1002/ejhf.2728. 2023
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.
Anker, SD; (...); Packer, M
Article. 2023
Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT
Ferreira, J.; (...); Zannad, F
Article. 10.1007/s00392-021-01962-4. 2022
Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT.
Ferreira, JP; (...); Zannad, F
Article. 10.1007/s00392-021-01962-4. 2022
Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI
Pitt, B, Ferreira, J., Zannad, F
Editorial Material. 10.1093/eurheartj/ehab717. 2022
winratiotest: A command for implementing the win ratio and stratified win ratio in Stata
Gregson J., Ferreira J.P., Collier T.
Article. 10.1177/1536867X231196480. 2023
winratiotest: A command for implementing the win ratio and stratified win ratio in Stata.
Gregson, J, Ferreira, JP, Collier, T
Article. 10.1177/1536867X231196480. 2023
Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings
Ferreira, JP; (...); McMurray, JJV
Article. 10.1002/ehf2.13731. 2022
Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings.
Ferreira, JP; (...); McMurray, JJ
Article. 10.1002/ehf2.13731. 2022
Aortic Valve Surgery With Stented Versus Stentless Bioprosthesis In Patients With Active Infective Endocarditis
Projeto de fim de curso
Colaboradores: Joaquim Adelino Correia Ferreira Leite Moreira
Freedom And Smart Solo Stentless Bioprosthesis For Aortic Valve Replacement - Clinical And Hemodynamic Evaluation-Systematic Review And Meta-Analysis
Projeto de fim de curso
Colaboradores: Francisca Almeida Saraiva
